Clinical Trial Update: A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 study of Intismeran Autogene (V940) in combination with pembrolizumab for cutaneous squamous cell carcinoma (V940-007) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Intismeran Autogene (V940) (V940)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Squamous Cell, Skin Neoplasms | Phase 2, Phase 3 | Status: COMPLETED